Phaseline

Targets › MBL

MBL (Mannose-binding protein C): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Oct 2027.

Calcium-dependent lectin, which acts as a pattern recognition receptor that initiates the lectin pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. Specifically recognizes and binds the mannose moiety of carbohydrates on the pathogen surface, activating the MASP1 serine protease and initiating the…. (UniProt, P11226)

Open in Phaseline: the race on MBL, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Menarini GroupMeropenem
Bacterial penicillin-binding protein inhibitor
MBLPhase 2Gram Negative InfectionsOct 2027

Conditions

Gram Negative Infections (1)

Modalities

small molecule (1)

Companies

Menarini Group (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.